Literature DB >> 29845471

Design and Interpretation of Noninferiority Trials.

Werner Vach1,2, Beryl Primrose Gladstone3.   

Abstract

Mesh：

Year:  2018        PMID： 29845471      PMCID： PMC6082190          DOI： 10.1007/s11606-018-4503-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  3 in total

1.  2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

Authors:  Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay Patel; Maximilian von Eynatten; Klaus A Dugi; Hans-Juergen Woerle
Journal:  Lancet       Date:  2012-06-28       Impact factor: 79.321

Review 2.  Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.

Authors:  Scott K Aberegg; Andrew M Hersh; Matthew H Samore
Journal:  J Gen Intern Med       Date:  2017-09-05       Impact factor: 5.128

3.  Phase IV non-inferiority trials and additional claims of benefit.

Authors:  Rosemarie D L C Bernabe; Grace Wangge; Mirjam J Knol; Olaf H Klungel; Johannes J M van Delden; Anthonius de Boer; Arno W Hoes; Jan A M Raaijmakers; Ghislaine J M W van Thiel
Journal:  BMC Med Res Methodol       Date:  2013-05-30       Impact factor: 4.615
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.